Assessment of Reperfusion Efficacy of Altelyse Versus Actilyse in Patients with Acute Myocardial Infarction: A Phase 3, Randomized, Double-Blinded, Non-inferiority Clinical Trial.
Mohammad Reza Beyranvand, Mohammad Asadpour Piranfar, Masoud Solaymani-Dodaran, Nahid Mohebbi, Reyhaneh Taati, Mehdi Sheibani, Mohammadreza Shahami, Safdar Masoumi, Saeid Shahraz, Hootan Manhoobi
Clin Drug Investig 45(2) 101-110
摘要
摘要
BACKGROUND: Primary percutaneous coronary intervention (PPCI) and fibrinolytic or thrombolytic therapy are common treatments for ST-elevation myocardial infarction (STEMI). Primary percutaneous coronary intervention is more effective than thrombolytic therapy, but fibrinolytic therapy is still a preferable option for patients with limited access to healthcare. Alteplase is a tissue plasminogen activator (tPA) used to treat acute myocardial infarction, acute ischemic stroke, and pulmonary embolism. OBJECTIVE: This study aims to compare the efficacy and safety of Altelyse (bio-similar Alteplase, Arena Life Science Company, Tehran, IRAN) versus the brand name Actilyse® (Boehringer Ingelheim, GERMANY) in patients with STEMI. METHODS: In this phase 3, double-blind, randomized trial, we assigned patients with STEMI to receive Altelyse or Actilyse, an intravenous bolus of 15 mg followed by an infusion of 0.75 mg/kg over 30 min (with a maximum dose of 50 mg) and continued with 0.50 mg/kg over 60 min (with a maximum dose of 35 mg). The primary endpoint was total ST-segment resolution (STR) in all leads with ST-segment elevations after 90 min of receiving fibrinolytic therapy. RESULTS: A total of 153 STEMI patients received Actilyse (79 patients) or Altelyse (74 patients). The mean total STR in all leads with ST elevation after 90 min was - 45.89 ± 32.92% and - 37.11 ± 35.28% in the Altelyse and Actilyse groups, respectively (the mean difference [95% confidence interval]: - 8.77 [- 19.92, 2.36]; p-value for non-inferiority: 0.0004). CONCLUSIONS: Among patients with STEMI, Altelyse was non-inferior to Actilyse with respect to STR after 90 min. TRIAL REGISTRY: Trial Registration Number, Date: IRCT20190729044366N1, 2019-05-25.
KM 提取结果
0 个 Figure · 0 个 KM 面板